Brief: Beyondspring Announces Positive Topline Results From Its Protective-2 Phase 3 Registrational Trial Of Plinabulin In Combination With Pegfilgrastim For Prevention Of Chemotherapy-Induced Neutropenia
16/11/2020 12:11
Nov 16 (Reuters) - Beyondspring Inc BYSI.O :
* BEYONDSPRING ANNOUNCES POSITIVE TOPLINE RESULTS FROM ITS
PROTECTIVE-2 PHASE 3 REGISTRATIONAL TRIAL OF PLINABULIN IN
COMBINATION WITH PEGFILGRASTIM FOR PREVENTION OF
CHEMOTHERAPY-INDUCED NEUTROPENIA
* BEYONDSPRING INC - PLINABULIN IN COMBINATION WITH
PEGFILGRASTIM
MET PRIMARY ENDPOINT
* BEYONDSPRING INC - STUDY ALSO MET STATISTICALLY
SIGNIFICANT
IMPROVEMENT IN KEY SECONDARY ENDPOINTS
Source text for Eikon: ID:nGNX57Y0w1
Further company coverage: BYSI.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Beyondspring
See all newsBrief: Beyondspring Inc Entered Into Open Market Sale Agreement Under Which Co May Offer And Sell Up To 9.2 Million Ordinary Shares
Brief: Beyondspring Announces FDA Fast Track Designation For Plinabulin In Post-Ici Non-Squamous Nsclc And Strategic Transaction To Advance Global Phase 3 Dublin-4 Trial Toward Planned Interim Analysis
NASDAQ RESUMED AT 12:26 PM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 12:21 PM
Brief: Beyondspring Announces Leadership Transition To Deliver Focused Execution On Its Confirmatory Dublin-4 Program And Long-Term Value